Ignite Creation Date:
2024-05-06 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 2:19 PM
Study NCT ID:
NCT05153187
Status:
COMPLETED
Last Update Posted:
2024-04-03
First Post:
2021-11-29
Brief Title:
Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positiveHuman Epidermal Growth Factor Receptor-2-negative HRHER2- Advanced Breast Cancer An Analysis of Administrative Claims Data in Japan
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Descriptive Analyses of Clinical Characteristics and Treatment Patterns of Breast Cancer Patients Initiating Palbociclib IbranceRegistered Treatment in Japan by Using MDV Database
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a retrospective observational study focusing on patients diagnosed with advanced breast cancerABC in Japan using de-identified claim data from Medical Data Vision MDV database
The primary objective of this study is to describe patient demographics treatment patterns and treatment duration of palbociclib and subsequent treatment patterns and treatment duration after palbociclib-based therapy among ABC patients in Japan The secondary objective of the study is to describe patient demographics treatment patterns of ABC patients and treatment duration of endocrine therapy and subsequent treatment patterns and treatment duration after endocrine therapy among ABC patients in Japan
The primary objective of this study is to describe patient demographics treatment patterns and treatment duration of palbociclib and subsequent treatment patterns and treatment duration after palbociclib-based therapy among ABC patients in Japan The secondary objective of the study is to describe patient demographics treatment patterns of ABC patients and treatment duration of endocrine therapy and subsequent treatment patterns and treatment duration after endocrine therapy among ABC patients in Japan
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None